|
|
Volumn 36, Issue 3, 2010, Pages 181-182
|
|
Implanon® failure in patients on antiretroviral medication: The importance of disclosure
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMPRENAVIR;
ATAZANAVIR;
EFAVIRENZ;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ETONOGESTREL;
LOPINAVIR;
NELFINAVIR;
NEVIRAPINE;
RITONAVIR;
SAQUINAVIR;
3 KETO DESOGESTREL;
3-KETO-DESOGESTREL;
ANTIRETROVIRUS AGENT;
CONTRACEPTIVE AGENT;
DESOGESTREL;
ADULT;
AMENORRHEA;
ANTIVIRAL THERAPY;
CASE REPORT;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG METABOLISM;
DRUG RELEASE;
DRUG TREATMENT FAILURE;
ECTOPIC PREGNANCY;
FEMALE;
HORMONAL CONTRACEPTION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LETTER;
PATIENT COUNSELING;
PHYSICIAN;
PREGNANCY TERMINATION;
SECOND TRIMESTER PREGNANCY;
SELF DISCLOSURE;
VIRUS LOAD;
DOCTOR PATIENT RELATION;
DRUG INTERACTION;
INTERPERSONAL COMMUNICATION;
STANDARD;
TREATMENT FAILURE;
ADULT;
ANTI-RETROVIRAL AGENTS;
CONTRACEPTIVE AGENTS, FEMALE;
DESOGESTREL;
DRUG INTERACTIONS;
FEMALE;
HIV INFECTIONS;
HUMANS;
PHYSICIAN-PATIENT RELATIONS;
SELF DISCLOSURE;
TREATMENT FAILURE;
TRUTH DISCLOSURE;
|
|
EID: 77954848144
PISSN: 14711893
EISSN: None
Source Type: Journal
DOI: 10.1783/147118910791749164 Document Type: Letter |
|
Times cited : (24)
|
|
References (5)
|
